Corcept Therapeutics Incorporated (HTD.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 09:24PM CEST. Market open.
| Previous Close | 21.24 |
| Open | 21.34 |
| Bid | 20.76 x 63700 |
| Ask | 21.27 x 61200 |
| Day's Range | 20.87 - 21.34 |
| 52 Week Range | 19.40 - 31.60 |
| Volume | |
| Avg. Volume | 19 |
| Market Cap | 2.2B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 23.72 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- Zacks
Corcept (CORT) Completes Enrollment in Phase II ALS Study
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
- Zacks
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
© 2024 Yahoo. All rights reserved.